The BCL2 inhibitor venetoclax, in combination with hypomethylating agent therapy has quickly become a standard of care treatment option for newly diagnosed, older and intensive chemotherapy-ineligible patients with AML, due to clinically meaningful improvements in remission rates and overall survival41. This evidence concerns the gene BCL2 and acute myeloid leukemia.